Eurocine Vaccines´ newly added HSV-2 vaccine candidate gains patent protection in South Korea
Eurocine Vaccines has received a Notice of Decision to Grant from the Korean Intellectual Property Office, covering inventions relevant for the newly added vaccine candidate against HSV-2, Herpes Simplex Virus Type 2. Adding South Korea to the territories with granted patents is well in line with the company´s global patent strategy as it is considered one of the four most important pharmaceutical markets in Asia.
The received Notice of Decision to Grant not only provides strengthened protection for the technology, but it also validates the level of innovation for the innovation. The patent is valid until 2037.
- Patents with a commercially relevant protection constitutes a crucial part of our work, onboarding new candidates. The HSV-2 vaccine candidate is no exception, where patents today are approved or pending for major markets worldwide, says CEO Hans Arwidsson.
Previous News Releases about the HSV-2 vaccine candidate include:
Expansion of portfolio with a therapeutic HSV-2 vaccine candidate
Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Strategic development plan for the newly added therapeutic HSV-2 vaccine candidate
Read more about our portfolio, vaccine candidates and needs they address.
Eurocine Vaccines´ portfolio
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.